Q Bio Unveils New MRI Technology - Tensor Field Mapping - Advancing Measurement in Medical Imaging

Instant quantifiable data from MRI imaging enables unparalleled diagnostic benchmarking and insights

PALO ALTO, Calif.--(BUSINESS WIRE)-- Q Bio Inc., an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM), a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable. Unlike traditional MRIs that provide qualitative data prone to machine or clinical variations, TFM delivers quantitative, harmonized imaging data that can be immediately accessed by AI to accelerate diagnostics.

“For decades, MRI technology has been invaluable in diagnosing a wide range of medical conditions, yet it has been limited by its qualitative nature and the variability of the data,” said Jeff Kaditz, Founder and CTO / CEO, Q Bio. “With the introduction of Tensor Field Mapping, we are taking a quantum leap forward, making multi-parametric quantification of tissues reproducible across machines, which is key to AI in MRI and personalized medicine.”

TFM is the result of extensive research and development by Q Bio’s team of experts in medical imaging, physics, and computational science, and will make its debut in the company’s upcoming Mark I full body scanner. The technology provides quantifiable data lacking in traditional MRIs so that properties of tissues can be measured and benchmarked on an ongoing basis. This advancement is crucial for the accurate diagnosis and treatment of diseases by enabling consistent and reliable imaging data that can be shared, pooled and compared, regardless of machines and clinical settings.

“Quantified MRIs have been anticipated for over 25 years, TFM has been the breakthrough that has made them the reality,” said Thomas Witzel, VP of Imaging at Q Bio, who spearheaded the development. “By modeling the entire imaging process without idealizing assumptions about the hardware, we’re not only enhancing the quality of MRI data but also paving the way for the development of new MRI equipment optimized for speed and patient comfort.”

Key capabilities of TFM include:

• A 100-fold reduction in computational power requiring only a single GPU;
• Imaging harmonization across hardware, software and clinical variations for sharing and knowledge pooling;
• Maxwell regularization which ensures accurate coil sensitivity modeling;
• Advanced field calibration and motion reconstruction techniques that enhance data accuracy and integrity.

“Tensor Field Mapping is more than an innovative technology; it’s a vision for the future of medical imaging where frequency, accuracy, and benchmarking with commodity radiomic data is possible,” added Clarissa Shen, COO, Q Bio. “We look forward to sharing our collaborations with healthcare providers and researchers to bring the benefits of TFM to patients around the world.”

Q Bio Inc. is committed to advancing medical imaging technology and improving patient outcomes. In addition to TFM’s upcoming debut in the Mark I full body scanner, the company also plans to explore the applicability of other hardware options. With the launch of Tensor Field Mapping, the company is at the forefront of a new era in diagnostics and personalized medicine.

ABOUT Q BIO INC.

Founded in 2015 by serial entrepreneur Jeff Kaditz, Dr. Michael Snyder and Dr. Garry Choy, Q Bio gives you a deeper understanding of your body and how it’s changing, so you have more control over your health. Q Bio’s platform is a quantitative, clinically-relevant assessment of personal human health. We believe in making preventive health available to everyone so that treatable diseases no longer take lives.

Investors include Andreessen Horowitz, Khosla Ventures, Founders Fund, Kaiser Foundation Hospitals and others. For more information, visit q.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409787415/en/